NAAA
NBIX icon

New Age Alpha Advisors’s Neurocrine Biosciences NBIX Stock Holding History

New Age Alpha Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.01M Sell
22,837
-497
-2% -$65.9K 0.14% 212
2025
Q4 		$3.31M Buy
23,334
+2,754
+13% +$399K 0.14% 199
2025
Q3 		$2.89M Sell
20,580
-624
-3% -$84.5K 0.12% 234
2025
Q2 		$2.67M Buy
21,204
+653
+3% +$74.9K 0.12% 260
2025
Q1 		$2.27M Sell
20,551
-1,812
-8% -$230K 0.1% 289
2024
Q4 		$3.05M Buy
+22,363
New +$2.77M 0.12% 239

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

New Age Alpha Advisors's NBIX Position: Q1 2026 in Review

New Age Alpha Advisors reduced its Neurocrine Biosciences (NBIX) stake by 2.1% in Q1 2026, selling an estimated $65.9K and leaving 22,837 shares worth $3.01M. The position accounts for 0.14% of the portfolio, ranked #212.

New Age Alpha Advisors first reported a position in NBIX in Q4 2024 and has held it in 6 quarters since. The position peaked at $3.31M in Q4 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • New Age Alpha Advisors held 22,837 shares of Neurocrine Biosciences worth $3.01M as of Q1 2026.
  • New Age Alpha Advisors sold 497 Neurocrine Biosciences shares in Q1 2026, an estimated $65.9K.
  • Neurocrine Biosciences made up 0.14% of New Age Alpha Advisors's portfolio in Q1 2026, its #212 holding.
  • New Age Alpha Advisors first reported a position in Neurocrine Biosciences in Q4 2024 and has held it in 6 quarters since.
  • New Age Alpha Advisors's Neurocrine Biosciences position peaked at $3.31M in Q4 2025.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on New Age Alpha Advisors's 13F filing for Q1 2026, filed 11 May 2026.